Drug Profile
MDL 27393
Latest Information Update: 02 Sep 1998
Price :
$50
*
At a glance
- Originator Aventis
- Class Antivirals; Polyamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 02 Sep 1998 No-Development-Reported for Cytomegalovirus infections treatment in USA (Unknown route)
- 11 Jul 1995 Preclinical development for Cytomegalovirus infections treatment in USA (Unknown route)